Results 131 to 140 of about 20,805 (196)

Development and Validation of Cell-Based Bioassay for the Detection of Neutralizing Antibodies to Ocrelizumab in Human Serum Using Antibody-Dependent Cell-Mediated Cytotoxicity Test in a Reporter Cell Line Expressing FcγRIIIa. [PDF]

Antibodies (Basel)
Strizhakova O, Poroshin G, Pershin A, Bakhareva Y, Shevchenko I, Lyagoskin I, Shukurov R, Khamitov R.   +7 more
europepmc   +1 more source

Oncolytic Herpes Virus G47Δ Potentiates ADCC-Inducing Molecular Targeted Therapy via Coordinated Activation of Innate and Adaptive Immune Responses. [PDF]

Mol Cancer Ther
Nagatomo T, Iwai M, Tanaka M, Nishino H, Todo T.   +4 more
europepmc   +1 more source

Fc effector functions in RNA viral infections: mechanisms of antiviral immunity and implications for vaccine design. [PDF]

Front Immunol
Zhang J, Li C, Wu Y, Wang L, Yu J, Wang A, Kong W, Ning M, Chen J, Chen Y.   +9 more
europepmc   +1 more source

Comparison of four different in vitro assays for prediction of potential RBC antibody clinical significance. [PDF]

Transfusion
Noa YR, Salou C, Beshai M, Cen SY, Hillis LK, Billingsley K, Branch DR.   +6 more
europepmc   +1 more source

A fully human afucosylated anti-GARP antibody PBA-0111 drives anti-tumor immunity through combined ADCC induction and TGF-β1 pathway blockade. [PDF]

Front Immunol
Spee P, Litwin M, Trojanowski D, Burns C, Dudek A, Gołdyn E, Sołtys K, Sobecki M, Świderska A, Matyjaszczyk I, Orłowski M, Mamczur P, Kolodziejczyk R, Piliuhin D, Xu J, Krzywińska E, Deshmukh S, Klaus T, Świderek E, Gillespie K, Turner A, Jenkins W, Frazier J, Gundle KR, Weinberg J, Veitonmäki N.   +25 more
europepmc   +1 more source

A mathematical model of antibody-dependent cellular cytotoxicity (ADCC) [PDF]

Journal of Theoretical Biology, 2018
Immunotherapies exploit the immune system to target and kill cancer cells, while sparing healthy tissue. Antibody therapies, an important class of immunotherapies, involve the binding to specific antigens on the surface of the tumour cells of antibodies that activate natural killer (NK) cells to kill the tumour cells.
David Gavaghan, Helen Byrne
exaly   +3 more sources